Tscan therapeutics expands clinical team with the appointment of dawn pinchasik, m.d., m.s., as vice president, clinical development

Waltham, mass., feb. 06, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of dawn pinchasik, m.d., m.s., as vice president, clinical development. dr. pinchasik brings to tscan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.
TCRX Ratings Summary
TCRX Quant Ranking